

**Effect of steroid-releasing sinus implants after  
endoscopic sinus surgery (ESS) on postoperative  
outcomes: A meta analytical study**

Meta-Analysis Study

Submitted for partial fulfillment of Master  
Degree in Otorhinolaryngology

**By:**

**Michael Mounir Stefan**

M.B.B.Ch

**Supervised by:**

**Prof. Dr. Nabil Abdel-Razik Rabie**

Professor of Otorhinolaryngology

Faculty of medicine-Ain Shams University

**Dr. Tamer Shoukry Sobhy**

Ass. Professor of Otorhinolaryngology

Faculty of medicine-Ain Shams University

**Dr. Ahmed Mahmoud Maarouf**

Lecturer of Otorhinolaryngology

Faculty of medicine-Ain Shams University

**Faculty of Medicine**

**Ain Shams University**

**(2018)**

# Acknowledgments

*First and above all my deepest gratitude and thanks to Allah for blessing this work, until it has reached its end, as a part of his generous help throughout my life.*

*I would like to express my very great appreciation to Prof. Dr. Nabil Abdel-Razik Rabie, Professor of ENT, Faculty of medicine, Ain Shams University, for his valuable and constructive suggestions during the planning and development of this research work. His willingness to give his time so generously has been very much appreciated.*

*I am also delighted to express my deepest gratitude to Dr. Tamer Shoukry Sobhy, Ass. Professor of ENT, Faculty of medicine, Ain Shams University, for his patient guidance, enthusiastic encouragement and useful critiques of this research work.*

*I would like also to express my sincere appreciation to Dr. Ahmed Mahmoud Maarouf, Lecturer of ENT, Faculty of medicine, Ain Shams University, for his continuous unlimited help, unlimited patience and close supervision throughout the entire research.*

*Michael Mounir Stefan*

# **Index**

| <i><b>Title</b></i>             | <i><b>Page</b></i> |
|---------------------------------|--------------------|
| <b>Acknowledgments</b>          | <b>1</b>           |
| <b>Index</b>                    | <b>2</b>           |
| <b>Appendix</b>                 | <b>3</b>           |
| <b>Introduction</b>             | <b>7</b>           |
| <b>Aim of the Work</b>          | <b>10</b>          |
| <b>Review of the Literature</b> |                    |
| • <b>Anatomy of the nose</b>    | <b>11</b>          |
| • <b>Functions of the nose</b>  | <b>16</b>          |
| • <b>Chronic rhinosinusitis</b> | <b>19</b>          |
| • <b>Stents</b>                 | <b>33</b>          |
| <b>Materials and methods</b>    | <b>53</b>          |
| <b>Results</b>                  | <b>64</b>          |
| <b>Discussion</b>               | <b>83</b>          |
| <b>Conclusion</b>               | <b>89</b>          |
| <b>Recommendations</b>          | <b>90</b>          |
| <b>Summary</b>                  | <b>92</b>          |
| <b>References</b>               | <b>95</b>          |
| <b>Arabic Summary</b>           |                    |

# Appendix

## List of figures

| <b><i>Fig</i></b> | <b><i>Title</i></b>                                                                                                                           | <b><i>Page</i></b> |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| <b>1</b>          | Medial wall of the nose                                                                                                                       | 12                 |
| <b>2</b>          | Lateral wall of the nose                                                                                                                      | 13                 |
| <b>3</b>          | Comparison of the plots of nasal drug concentration <i>versus</i> time                                                                        | 34                 |
| <b>4</b>          | (A) Drug encapsulated in a biodegradable polymer matrix, and (B) Drug loaded microparticles are incorporated in a hydrogel to form an implant | 36                 |
| <b>5</b>          | A plot of percentage cumulative drug release from the implant <i>versus</i> time                                                              | 37                 |
| <b>6</b>          | Propel (A) and Propel mini (B) implants                                                                                                       | 47                 |
| <b>7</b>          | Single-use delivery systems for deployment of the Propel (A) and Propel mini (B) into the ethmoid cavity                                      | 47                 |
| <b>8</b>          | A typical design of a Relieva Stratus™ Microflow spacer                                                                                       | 49                 |
| <b>9</b>          | Deployment guide with access probe (top) and delivery sheath (bottom)                                                                         | 49                 |
| <b>10</b>         | Forest plot for the occurrence of significant adhesions                                                                                       | 66                 |
| <b>11</b>         | Funnel plot for the occurrence of significant adhesions                                                                                       | 67                 |
| <b>12</b>         | Forest plot for middle turbinate lateralization                                                                                               | 69                 |
| <b>13</b>         | Funnel plot for middle turbinate lateralization                                                                                               | 70                 |
| <b>14</b>         | Forest plot for the polyp formation                                                                                                           | 72                 |
| <b>15</b>         | Funnel plot for the polyp formation                                                                                                           | 73                 |
| <b>16</b>         | Forest plot for the need for oral steroid intervention                                                                                        | 75                 |
| <b>17</b>         | Funnel plot for the need for postoperative intervention                                                                                       | 76                 |
| <b>18</b>         | Forest plot for the need for postoperative intervention                                                                                       | 78                 |
| <b>19</b>         | Funnel plot for the need for postoperative intervention                                                                                       | 79                 |
| <b>20</b>         | Forest plot for the need for surgical adhesion intervention                                                                                   | 81                 |
| <b>21</b>         | Funnel plot for the need for surgical adhesion intervention                                                                                   | 82                 |

**List of tables**

| <b><i>Table</i></b> | <b><i>Title</i></b>                                                 | <b><i>Page</i></b> |
|---------------------|---------------------------------------------------------------------|--------------------|
| <b>1</b>            | Factors related to pathophysiology of CRS                           | 20                 |
| <b>2</b>            | Factors associated with diagnosis of CRS                            | 24                 |
| <b>3</b>            | Estimated absolute bioavailability of INCs                          | 30                 |
| <b>4</b>            | Comparison of the major advantages and limitations of DESs          | 52                 |
| <b>5</b>            | Endoscopic grading form                                             | 56                 |
| <b>6</b>            | Summary of the included articles                                    | 57                 |
| <b>7</b>            | Summary of the excluded articles and the reason for exclusion       | 58                 |
| <b>8</b>            | Meta-analysis for the occurrence of significant adhesions           | 65                 |
| <b>9</b>            | Meta-analysis for the occurrence of middle turbinate lateralization | 68                 |
| <b>10</b>           | Meta-analysis for the polyp formation                               | 71                 |
| <b>11</b>           | Meta-analysis for the need for oral steroid intervention            | 74                 |
| <b>12</b>           | Meta-analysis for the need for postoperative intervention           | 77                 |
| <b>13</b>           | Meta-analysis for the need for surgical adhesion intervention       | 80                 |

**List of abbreviations**

|         |                                                            |
|---------|------------------------------------------------------------|
| AAO-HNS | American Academy of Otolaryngology – Head and Neck Surgery |
| ABRS    | Acute bacterial rhinosinusitis                             |
| AERD    | Aspirin-exacerbated respiratory disease                    |
| AFRS    | Allergic fungal rhinosinusitis                             |
| AR      | Allergic rhinitis                                          |
| ARS     | Acute rhinosinusitis                                       |
| AS      | Absorbable spacer                                          |
| CF      | Cystic fibrosis                                            |
| CI      | Confidence interval                                        |
| CRS     | Chronic rhinosinusitis                                     |
| CRSsNP  | CRS without (sine) nasal polyposis                         |
| CRSwNP  | CRS with nasal polyposis                                   |
| CT      | Computerized tomography                                    |
| DAC     | Dimethyl aminopropyl carbodiimide                          |
| DESS    | Drug eluting stents                                        |
| DF      | Degree of freedom                                          |
| EP3OS   | European Position Paper on Rhinosinusitis                  |
| ESS     | Endoscopic sinus surgery                                   |
| EVAC    | Ethyl vinyl acetate                                        |
| FDA     | Food and Drug administration                               |
| FEM     | Fixed- effects method                                      |
| FESS    | Functional endoscopic sinus surgery                        |
| GERD    | Gastroesophageal reflux                                    |
| HPLC    | High performance liquid chromatography                     |
| IG      | Immunoglobulin                                             |
| IL      | Interleukin                                                |
| INCs    | Intranasal corticosteroids                                 |
| LOA     | Lysis of adhesions                                         |
| MF      | Mometasone furoate                                         |
| MCC     | Mucociliary Clearance                                      |
| MRI     | Magnetic resonance imaging                                 |
| MT      | Middle turbinate                                           |

|        |                                       |
|--------|---------------------------------------|
| NAS    | Non absorbable spacer                 |
| NDGA   | Nordihydroguaiaretic acid             |
| NMC    | Nasal Mucociliary Clearance           |
| NP     | Nasal Polyposis                       |
| NSAIDs | Nonsteroidal anti-inflammatory drugs  |
| OMC    | Ostiomeatal complex                   |
| PA     | Polyvinyl acetate                     |
| PBS    | Phosphate-buffered saline             |
| PEG    | Polyethylene glycol                   |
| PLA    | Polylactic acid                       |
| PLG    | Polyactide-co-glycolide               |
| PLGA   | Polylactic-co-glycolic acid           |
| PVA    | Polyvinyl alcohol                     |
| Q      | Cochran Q statistic                   |
| QOL    | Quality of life                       |
| RCT    | Randomized controlled trial           |
| REM    | Random-effects method                 |
| RR     | Relative risk                         |
| RS     | Rhinosinusitis                        |
| SE     | Standard error                        |
| SEM    | Standard error of the mean            |
| SEMD   | Standard error of the mean difference |
| SMD    | Standardized mean difference          |
| TH     | T helper                              |
| TSS    | Toxic shock syndrome                  |
| VRS    | Viral rhinosinusitis                  |

## **Introduction**

Rhinosinusitis (RS) is an extremely prevalent disorder that affects an estimated 14% of the adult population. RS is a significant and increasing health problem which results in a large economic burden, especially when recurs, it has been shown that subsequent episodes cost successively more for diagnostic tests and therapy. It is thought to be more common in childhood than in adults. It affects all races and socioeconomic backgrounds. The incidence is higher in spring, winter, and fall than it is during the summer months (**Anand, 2004**).

Chronic rhinosinusitis (CRS) is an inflammatory disease of the mucosa of the nose and paranasal sinuses that is present for at least 12 weeks. A diagnosis of CRS is based on the EPOS (European position paper on rhinosinusitis and nasal polyps) criteria both subjective and objective criteria, which are the presence of distinctive symptoms, (e.g. nasal obstruction and nasal discharge) and either endoscopic signs or computed tomography (CT) images showing mucosal changes within the ostiomeatal complex, sinuses, or both (**Fokkens et al., 2012**).

Multiple factors have been implicated in the development of CRS, including host and environmental factors. Host factors, such as immunodeficiency and eicosanoid dysregulation, also contribute to refractory infections or inflammation and have a significant impact on the severity of CRS. Environmental factors, such as bacteria, biofilms, fungi and allergens, have been described as disease modifying factors that lead to inflammation of the mucosa of the nose and paranasal cavities (**Kennedy, 2004 and Tan et al., 2010**).



Although medical treatments offer relief for most CRS patients, functional endoscopic sinus surgery (FESS) is commonly performed. Surgical treatment is not considered a curative treatment for CRS; approximately 14% of CRS patients who undergo surgery will require revision ESS (**Bhattacharyya, 2004**).

There are many reasons for surgical failure including scarring of the sinus ostia, adhesion formation, middle turbinate lateralization and persistent inflammations. Controlling for these postoperative issues may lead to better long-term outcomes (**Otto and DelGaudio, 2010**).

Sinus stents are devices that are inserted into the nose, sinuses or both following FESS to prevent stenosis of the sinus openings during the postoperative healing period (**Weber et al., 2000**).

Sinus stents may be composed of non-absorbable alloplastic materials (e.g. silicone, plastic), to be removed in the office setting after a period of several days; or absorbable biomaterials (e.g. bovine gelatin, poly (lactic-co-glycolic acid), which degrade in a controlled fashion over days to weeks following surgery (**Weitzel and Wormald, 2008**).

Sinus stents are also known as 'spacers' because they maintain separation between critical areas of healing to prevent synechia formation. For example, middle meatal stents provide a mechanical barrier between the middle turbinate and lateral nasal wall; the goal of stent placement here is to avoid middle turbinate lateralization, a complication that can lead to recurrence and propagation of chronic rhinosinusitis (**Weitzel and Wormald, 2008**).

Recent advances in biomaterial technology have resulted in the development of corticosteroid-coated sinus stents, which can elute the drug in a controlled fashion via a bioabsorbable core. The drug-eluting stents offer the

potential for the dual benefits of mechanical spacing and anti-inflammatory pharmacotherapy. The slow release of corticosteroid aims to decrease mucosal oedema and expedite wound healing (**Bednarski and Kuhn, 2009**).

Recent studies have shown that steroid-eluting sinus stents can preserve sinus patency and enhance mucosal wound healing after FESS by reducing inflammation, polyposis and the formation of adhesion (**Han et al., 2014**).

## **Aim of the work**

The aim of this work is a meta-analysis to evaluate the steroid-releasing sinus implants placement in chronic rhinosinusitis (CRS) patients after functional endoscopic sinus surgery (FESS) in order to assess its efficacy.


## **Anatomy of the nose**

The nose is an important part of the face; it gives the individual his characteristic appearance. The nose is divided into 2 parts: The external nose and the internal nose (nasal cavities). The nasal cavity is divided by midline partition (the nasal septum) into right and left chambers. It extends from the nostrils in front into the choanae behind (where it opens into the nasopharynx) the entrance to the nasal cavity is called the nasal vestibule which ends at the mucocutaneous junction, it is lined by skin and contains skin appendages. The rest of nasal cavity lined by respiratory mucosa (pseudo- stratified columnar ciliated epithelium), and small area lined by olfactory epithelium (**Nouraei et al., 2009**).

Each cavity has a roof, floor, medial and lateral walls.

**The floor** is formed by the palatine process of the maxilla and the horizontal process of palatine bone.

**The roof** is narrow and is formed (from behind forward) by the body of the sphenoid, cribriform plate of the ethmoid which contain numerous tiny perforations which transmit sensory fibers to the olfactory bulbs and the frontal bone.



**Figure (1):** Medial wall of the nose. Quoted from (*Bradoo, 2005*).

**The medial wall** (the nasal septum) is an osteocartilaginous partition covered by adherent mucoperichondrium and mucoperiosteum. The upper part is formed by the perpendicular plate of the ethmoid bone, the posterior part by the vomer and the anterior portion is formed by septal cartilage as shown in figure 1.


**The lateral wall** is the most complex and variable, it supports the 3 turbinates (inferior, middle, superior and sometimes there is even a supreme) as shown in figure 2. The groove below each turbinate is referred to as a meatus.

**Inferior meatus:** contain the opening of nasolacrimal duct.

**Superior meatus:** receives the opening of the posterior ethmoid sinus.

**Spheno-ethmoidal recess:** is the area above the superior turbinate. It receives the opening of the sphenoid sinus.

**Comun Meatus:** vertical slot between all nasal turbinates and septum (**Bradoo, 2005**).



**Figure (2):** Lateral wall of the nose. Quoted from (*Bradoo, 2005*).

### Paranasal Sinuses

Sinuses are hollow spaces in the bones around the nose that connect to the nose through small narrow channels called ostia.

They can be divided into 2 groups:

(1) Anterior group: frontal, maxillary, anterior and middle ethmoidal air sinuses.

(2) Posterior group: posterior ethmoid and sphenoid sinuses. The anterior group drain into the middle meatus of the nose and the posterior ethmoid sinus drain into the

superior meatus and the sphenoid sinus drain into the sphenoethmoidal recess (**Lund, 1997**).

*The frontal sinuses* lies at the anterosuperior part of the middle meatus, as a small evagination, the frontal recess develops during the third month. This gradually deepens and by term a small diverticulum is present. The formation of the frontal sinuses occurs with gradual upwards expansion of the diverticulum into the frontonasal region. The sinus may, on rare occasions, develop as an extramural expansion of one of the anterior ethmoidal cells. Medially, the two sinuses come to lie in close proximity, divided by a thin intersinus septum. Situated in the eyebrow area of forehead bone of the skull. Usually asymmetrical, occasionally absent, in about 5% of us (**McLaughlin et al., 2001**).

*Maxillary sinuses* is the first to appear as an ectodermal depression just above the uncinate ridge on the inferior turbinate. This pit, which is the site of the eventual maxillary ostium in the central part of the middle meatus, deepens laterally and expands so that by term a cavity measuring 7 x 4 x 4 mm is present in bones of cheeks, one on each side. May grow to be as large as 15ml (**Oneal et al., 1999**).

*Ethmoid sinuses* developed during the fifth fetal month, as a small ectodermal evaginations on the lateral nasal wall and grow laterally into the ethmoid bone. By term, these diverticula are globular shaped and they continue to grow until late puberty, usually 6 to 10 per side, situated between the orbits, up to the skull base. Responsible for more complications from sinusitis than other sinuses (**Graney and Rice, 1998**).

*Sphenoid sinus* develops during the fourth fetal month, as an ectodermal pit in the posterosuperior aspect of the nasal capsule. At birth, it measures 2 x 2 x 1.5 mm and is still only rudimentary. In the fourth postnatal year, when the nasal capsule resorbs, sphenoid pneumatization